IP Valuation of Diagnostic Biomarker Company
The AMCO Approach
We identified and evaluated patents, research data, and proprietary biomarker panels, considering the demand for non-invasive diagnostics. Our valuation reflected the company’s potential impact in early disease screening and market growth in preventive healthcare.
Client Outcome
The valuation enabled the company to form a strategic partnership, enhancing its distribution capabilities and expanding its diagnostic offerings to a larger network of healthcare providers.
Instruction
AMCO was instructed by a diagnostics company developing biomarker-based blood tests for early disease detection. The company required an IP valuation to pursue a partnership with a global laboratory services provider.
Contact Us
AMCO Agency Limited
First Floor
85 Great Portland Street
London
W1W 7LT
+44 7973 600 500